دورية أكاديمية
أعرض في EDS

Cinnamaldehyde ameliorates STZ-induced diabetes through modulation of autophagic process in adipocyte and hepatic tissues on rats.

التفاصيل البيبلوغرافية
العنوان: Cinnamaldehyde ameliorates STZ-induced diabetes through modulation of autophagic process in adipocyte and hepatic tissues on rats.
المؤلفون: Ghazal NA; Department of Biochemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, EL-Hadara, POB 21561, Alexandria, Egypt., Agamia YT; Department of Biochemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, EL-Hadara, POB 21561, Alexandria, Egypt., Meky BK; Department of Biochemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, EL-Hadara, POB 21561, Alexandria, Egypt., Assem NM; Department of Biochemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, EL-Hadara, POB 21561, Alexandria, Egypt., Abdel-Rehim WM; Department of Biochemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, EL-Hadara, POB 21561, Alexandria, Egypt. wafaa.abdelreheam@alexu.edu.eg., Shaker SA; Department of Biochemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, EL-Hadara, POB 21561, Alexandria, Egypt.
المصدر: Scientific reports [Sci Rep] 2024 May 02; Vol. 14 (1), pp. 10053. Date of Electronic Publication: 2024 May 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Acrolein*/*analogs & derivatives, Acrolein*/pharmacology , Acrolein*/therapeutic use , Autophagy*/drug effects , Diabetes Mellitus, Experimental*/drug therapy , Diabetes Mellitus, Experimental*/metabolism , Liver*/drug effects , Liver*/metabolism , Liver*/pathology , Adipocytes*/drug effects , Adipocytes*/metabolism , Metformin*/pharmacology, Animals ; Male ; Rats ; Diet, High-Fat/adverse effects ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/metabolism ; MicroRNAs/metabolism ; MicroRNAs/genetics ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Streptozocin ; Blood Glucose/metabolism ; TOR Serine-Threonine Kinases/metabolism
مستخلص: Type 2 diabetes mellitus is a worldwide public health issue. In the globe, Egypt has the ninth-highest incidence of diabetes. Due to its crucial role in preserving cellular homeostasis, the autophagy process has drawn a lot of attention in recent years, Therefore, the purpose of this study was to evaluate the traditional medication metformin with the novel therapeutic effects of cinnamondehyde on adipocyte and hepatic autophagy in a model of high-fat diet/streptozotocin-diabetic rats. The study was conducted on 40 male albino rats, classified into 2 main groups, the control group and the diabetic group, which was subdivided into 4 subgroups (8 rats each): untreated diabetic rats, diabetic rats received oral cinnamaldehyde 40 mg/kg/day, diabetic rats received oral metformin 200 mg/kg/day and diabetic rats received a combination of both cinnamaldehyde and metformin daily for 4 weeks. The outcomes demonstrated that cinnamaldehyde enhanced the lipid profile and glucose homeostasis. Moreover, Cinnamaldehyde had the opposite effects on autophagy in both tissues; by altering the expression of genes that control autophagy, such as miRNA 30a and mammalian target of rapamycin (mTOR), it reduced autophagy in adipocytes and stimulated it in hepatic tissues. It may be inferred that by increasing the treatment efficacy of metformin and lowering its side effects, cinnamaldehyde could be utilized as an adjuvant therapy with metformin for the treatment of type 2 diabetes.
(© 2024. The Author(s).)
References: J Cell Mol Med. 2017 Dec;21(12):3679-3692. (PMID: 28766848)
Int J Biol Macromol. 2022 Apr 15;204:258-273. (PMID: 35143849)
Cell. 2017 Mar 9;168(6):960-976. (PMID: 28283069)
Adipocyte. 2015 Jul 15;5(1):11-21. (PMID: 27144092)
J Oncol. 2018 Aug 6;2018:5167829. (PMID: 30158978)
J Biol Chem. 2012 Feb 3;287(6):4148-56. (PMID: 22157765)
Int J Equity Health. 2015 Oct 12;14:93. (PMID: 26458543)
J Periodontol. 2018 Oct;89(10):1262-1271. (PMID: 29761921)
Cardiovasc Diabetol. 2021 Jan 30;20(1):30. (PMID: 33516224)
Methods Enzymol. 1990;186:421-31. (PMID: 2233309)
Int J Mol Sci. 2019 Jan 08;20(1):. (PMID: 30626110)
Cell. 2012 Apr 13;149(2):274-93. (PMID: 22500797)
Nurse Res. 2003 Jan 1;10(2):86-87. (PMID: 27702267)
Mol Metab. 2019 Sep;27S:S92-S103. (PMID: 31500836)
Nanomedicine (Lond). 2023 Feb;18(5):417-435. (PMID: 37166047)
Life Sci. 2016 Dec 1;166:149-156. (PMID: 27693527)
PLoS One. 2014 Jan 10;9(1):e83604. (PMID: 24427275)
Front Endocrinol (Lausanne). 2023 Sep 21;14:1228045. (PMID: 37810881)
Oxid Med Cell Longev. 2020 Mar 9;2020:8609213. (PMID: 32215179)
Nat Cell Biol. 2011 Feb;13(2):132-41. (PMID: 21258367)
Int J Mol Sci. 2018 Nov 29;19(12):. (PMID: 30501132)
Diabetologia. 2017 Sep;60(9):1577-1585. (PMID: 28776086)
Biomed Pharmacother. 2021 May;137:111286. (PMID: 33524789)
Cell Death Dis. 2013 Oct 17;4:e861. (PMID: 24136225)
Acta Pharmacol Sin. 2022 Mar;43(3):712-723. (PMID: 33980998)
Pharmaceutics. 2022 Oct 08;14(10):. (PMID: 36297569)
PLoS One. 2016 Mar 10;11(3):e0151104. (PMID: 26963814)
Biomarkers. 2022 May;27(3):270-277. (PMID: 35078379)
Biomol Ther (Seoul). 2014 Jan;22(1):47-54. (PMID: 24596621)
J Physiol Pharmacol. 2021 Feb;72(1):. (PMID: 34099588)
Cell. 2011 Nov 11;147(4):728-41. (PMID: 22078875)
JAMA. 2019 May 21;321(19):1926-1927. (PMID: 31009043)
Scand J Clin Lab Invest. 1985 Jun;45(4):315-20. (PMID: 4012216)
Autophagy. 2012 Apr;8(4):445-544. (PMID: 22966490)
EXCLI J. 2018 Jul 24;17:709-720. (PMID: 30190661)
J Pharm Sci. 2006 Nov;95(11):2543-52. (PMID: 16937336)
Chem Biol Interact. 2010 Jun 7;186(1):72-81. (PMID: 20363216)
Kidney Int. 2007 Jan;71(1):74-8. (PMID: 17082757)
Nature. 2008 Feb 28;451(7182):1069-75. (PMID: 18305538)
Phytother Res. 2024 Jan;38(1):117-130. (PMID: 37818728)
Sci Rep. 2015 Jan 21;5:7919. (PMID: 25605129)
BMC Cell Biol. 2018 Jun 19;19(1):7. (PMID: 29921218)
Nature. 2010 Jun 17;465(7300):942-6. (PMID: 20526321)
ScientificWorldJournal. 2018 Jun 6;2018:7405736. (PMID: 29977171)
J Nutr Biochem. 2020 Mar;77:108321. (PMID: 31869758)
Oxid Med Cell Longev. 2017;2017:9208489. (PMID: 28194256)
Cell Metab. 2010 Jun 9;11(6):449-51. (PMID: 20519116)
J Pak Med Assoc. 2020 Nov;70(11):2065-2069. (PMID: 33341863)
Cardiovasc Diabetol. 2012 Aug 10;11:95. (PMID: 22882757)
Diabetes Care. 2016 Aug;39 Suppl 2:S137-45. (PMID: 27440826)
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. (PMID: 21157483)
Oncotarget. 2017 Jan 31;8(5):7370-7383. (PMID: 28088783)
Pharmacol Res. 2005 Oct;52(4):313-20. (PMID: 15979893)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Biochem Biophys Res Commun. 2016 Aug 5;476(4):196-203. (PMID: 27208776)
Endocrinol Metab Clin North Am. 2006 Sep;35(3):491-510, vii-viii. (PMID: 16959582)
Nat Cell Biol. 2013 Jul;15(7):741-50. (PMID: 23685627)
Onco Targets Ther. 2020 May 19;13:4445-4455. (PMID: 32547075)
Semin Cell Dev Biol. 2014 Dec;36:121-9. (PMID: 25158238)
Antioxidants (Basel). 2017 Jan 19;6(1):. (PMID: 28106822)
Int J Nanomedicine. 2017 Apr 28;12:3433-3446. (PMID: 28496320)
Diabetes Care. 2006 Dec;29(12):2733-4. (PMID: 17130216)
Diabetologia. 2017 Apr;60(4):668-678. (PMID: 28004151)
Am J Med Sci. 2016 Apr;351(4):361-5. (PMID: 27079341)
Autophagy. 2015;11(1):46-59. (PMID: 25484077)
J Biol Chem. 1951 Nov;193(1):265-75. (PMID: 14907713)
J Biol Chem. 2009 Nov 6;284(45):31484-92. (PMID: 19758991)
المشرفين على المادة: 7864XYD3JJ (Acrolein)
SR60A3XG0F (cinnamaldehyde)
9100L32L2N (Metformin)
0 (MicroRNAs)
0 (Hypoglycemic Agents)
5W494URQ81 (Streptozocin)
0 (Blood Glucose)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
تواريخ الأحداث: Date Created: 20240502 Date Completed: 20240502 Latest Revision: 20240509
رمز التحديث: 20240509
مُعرف محوري في PubMed: PMC11066029
DOI: 10.1038/s41598-024-60150-2
PMID: 38698047
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-60150-2